The name Noopept is the brand name for N-phenylacetyl-L-prolylglycine-ethyl-ester.
Noopept was developed in 1997 as an improved version of the popular nootropic piracetam. It has a higher bioavailability, and is able to cross the blood-brain-barrier much more readily. This results in much more efficient effects from Noopept than any other racetam nootropic.
The standard dose of piracetam is 1200 mg, while the same effects are produced from just 20 mg of Noopept.
The Russian Academy of Medical Sciences has been testing oligopeptides like Noopet for decades. They were combining the amino acid proline (structural base for piracetam) with neuropeptides when they discovered GVS-111 (Noopept). This compound had the most dramatic improvement in neurological function, a very high-degree of safety, and exceptional bioavailability.
Noopept is the brand name for N-phenylacetyl-L-prolylglycine-ethyl-ester. Once Noopept crosses the blood brain barrier it’s almost completely metabolized into CPG (cycloprolylglycine) which is a neuropeptide with powerful downstream effects on learning and memory.